Skip to main content
Premium Trial:

Request an Annual Quote

Transgenomic's Q4 Sales Rise 9.4 Percent

NEW YORK (GenomeWeb News) - Transgenomic today said fourth-quarter revenues increased 9.4 percent as R&D spending rose roughly 28 percent and losses were cut by 91 percent.
 
Total receipts for the three months ended Dec. 31, 2006, increased to $5.8 million from $5.3 million year over year.
  
The growth came from sales of the company’s Discovery Services unit, OEM sales, and placements of the company’s WAVE system and related consumables, Transgenomic CEO Craig Tuttle said in a statement.
 
R&D spending increased to $641,000 from $502,000 year over year.
 
The company said net losses shrank to $1 million from $11.2 million in the year-ago period. The 2006 fourth-quarter results include a loss from discontinued operations of $164,000.
 
In the fourth quarter of 2005, Transgenomic took a loss of $9.4 million on discontinued operations as the company restructured its focus on its biosystems business and liquidated its nucleic acids manufacturing facility in Glasgow.
 
Transgenomic said it had around $5.9 million in cash and cash equivalents as of Dec. 31.

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.